Guest: Ali Mortazavi | CEO, Tangram Therapeutics (formerly E-Therapeutics), London, UK
Episode Summary:
Ali Mortazavi is not your typical biotech CEO. A computer scientist by training, former professional chess player, and veteran of financial markets, he invested in an RNAi company in 2012 — and then, by his own admission, made the crazy decision to become its CEO with zero background in biology, chemistry, or medicine.
What followed is a 14-year education in the brutal realities of drug development — and a front-row seat to the AI revolution now reshaping it. In this wide-ranging conversation, Mortazavi draws on his extraordinary personal story (fleeing revolutionary Iran as a child, arriving in London unable to speak English, rising through chess and finance) to offer a uniquely cross-disciplinary perspective on why biotech is stuck in a me-too loop, why the incentive system is the real bottleneck, and where AI is — and isn't — changing the game.
0:00 - Introduction & Ali's Background
1:07 - The Iranian Revolution at Nine Years Old
4:44 - Fleeing Iran, Arriving in London
6:38 - The Refugee Experience and Starting Over
7:49 - Computer Science in 1990
9:53 - Becoming a Professional Chess Player
11:06 - The Vishwanathan Anand Moment
13:17 - From Chess to Finance to Biotech CEO
14:44 - The Gleevec Illusion and the Reality of Drug Development
16:07 - Jay Bhattacharya, Reproducibility, and the PubMed Button
18:18 - LLMs as Scientific Compression Systems
20:15 - Why LLMs Give "The Average Answer" — The Co-Pilot Model
23:44 - Vibe Coding and the Explosion of Code
25:36 - AI Won't Replace 10x Coders — It Will Replace 90 of 100
26:16 - The GalNAC Case Study: 35 Years of Forgotten Innovation
31:10 - The Me-Too Algorithm and Biotech VC Incentives
34:40 - GLP-1s: Another 30 Years of Sitting Around
35:26 - The FDA, the XBI, and the Current Regulatory Landscape
40:43 - Can Politics Fix the Incentive System?
42:09 - Why Past Progress Happened Without AI
44:24 - Medical Ethics, Experimentation, and the Innovation Tradeoff
48:34 - Biotech Is Archaic: The Preclinical De-Risking Problem
50:05 - No Animal Model Actually Works
52:16 - Over-Regulation vs. Just Plain Hard
53:00 - The US Market as the Global Subsidy Engine
54:05 - China: Wake-Up Call, Not Innovator
56:25 - The London Market: "Don't Call It a Market"
58:52 - AI-Native Biotechs: Too Soon to Tell
59:36 - Where AI Works: Information. Where It Doesn't: Physics.
1:01:29 - Tangram Therapeutics and Libra OS
1:04:25 - The Future: SaaS Collapse, Medicine Returns to Fundamentals
1:07:36 - Closing: Hope, Broken Glass, and Early Adoption
Subscribe to The Doctor's Lounge: Apple Podcasts | Spotify | YouTube | RSS
Follow the Show: X: @DrsLoungePod
Follow the Guest: X: @AAMortazavi
Co-hosts: @anish_koka | @drdanchoi | @dutchrojas | @sdixitmd | @drdigiorgio
